 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Key Insights Given the large stake in the stock by institutions, BeiGene's stock price might be vulnerable to their...

BeiGene, Ltd. (NASDAQ:BGNE) is largely controlled by institutional shareholders who own 41% of the company

Clear Harbor Asset Management LLC acquired a new stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange...

Clear Harbor Asset Management LLC Acquires New Shares in BeiGene, Ltd. (NASDAQ:BGNE)

This is a signal that BGNE's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

BeiGene (BGNE, $152.02) Stochastic Oscillator left the oversold zone on March 22, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

BeiGene (BGNE, $152.02) price exceeded its 50-day Moving Average on March 22, 2024

This is a Bearish indicator signaling BGNE's price could decline from here. Traders may explore shorting the stock or put options...

BeiGene (BGNE, $152.02) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 22, 2024

This price move could be a signal that BGNE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

BeiGene (BGNE, $152.02) price may climb as it broke lower Bollinger Band on Mar 22, 2024

BeiGene (NASDAQ:BGNE  Get Free Report) had its target price increased by JPMorgan Chase  Co. from $184.00 to $186.00 in a research note issued on Tuesday, Benzinga reports. The firm...

BeiGene (NASDAQ:BGNE) Price Target Raised to $186.00 at JPMorgan Chase & Co.

BeiGene, Ltd. (NASDAQ:BGNE  Get Free Report) CEO John Oyler sold 37,668 shares of the firms stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an...

BeiGene, Ltd. (NASDAQ:BGNE) CEO John Oyler Sells 37,668 Shares

FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with...

FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA (tislelizumab-jsgr) as...

BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Volume (M)	125,955.00
52-Wk High	$266.67
52-Wk Low	$131.28

BGNE BeiGene

About

Feed

News

Sentiment

Earnings

Fundamentals